Weight Loss Drugs May Impact Brain’s Reward Centre, Study Warns
A recent study highlights potential effects of newer GLP-1 weight loss drugs, like oral versions such as danuglipron and orforglipron, on the brain’s reward system. Researchers from the University of Virginia found these drugs not only suppress appetite but also alter circuits linking the hindbrain to the central amygdala and dopamine neurons, reducing desire for pleasurable, high-calorie foods.
The study, published in Nature, used genetically engineered mice to show drugs engage a pathway that diminishes hedonic feeding—eating for pleasure—by curbing dopamine release in the nucleus accumbens. Lead researcher Ali D. Güler noted this goes beyond satiety, affecting motivation for rewards like cake.
These changes could influence addiction, impulse control, or overall pleasure perception, with some patients reporting less enjoyment or easier quitting of habits like smoking. Variations in side effects, such as nausea, may tie to how drugs hit these reward pathways differently.
Conducted on mice, the work suggests next-generation GLP-1 drugs penetrate deep brain areas, opening avenues for treating reward-related disorders beyond obesity. Human studies are needed to confirm effects.
